Overview

Gender

male

Investor Type

Investment Partner

Michael Schmertzler has served as a member of PTC's board of directors since August 2001 and as the Chairman of our board of directors since November 2004.

From 2008 to 2012, Michael Schmertzler served as Chief Executive Officer and a director of Kolltan Pharmaceuticals, Inc., a biotechnology company.

Since 2001, Michael Schmertzler has served as a Managing Director of Aries Advisors, LLC, the sub-advisor to Credit Suisse First Boston Equity Partners, L.P., a private equity fund, and the Chair of the investment committee.

From 1997 to 2001, Michael Schmertzler was Co-Head of United States and Canadian Private Equity at Credit Suisse First Boston, an investment banking company.

Prior to 1997,Michael Schmertzler held various management positions with Morgan Stanley and its affiliates, including President of Morgan Stanley Leveraged Capital Funds and head of Morgan Stanley’s biotechnology pharmaceuticals group, and was Managing Director and Chief Financial Officer of Lehman Brothers Kuhn Loeb, an investment banking firm.

Michael Schmertzler is currently a director of Lehman Commercial Paper Incorporated, a liquidating postbankruptcy subsidiary of Lehman Brothers Holdings, Incorporated. Mr. Schmertzler previously served as a director of Cytokinetics, Incorporated. Since 1978, he has been an Adjunct Professor at Yale University.

Michael Schmertzler received a B.A. from Yale College in Molecular Biophysics and Biochemistry, History and City Planning and an M.B.A. from the Harvard Business School.